Bausch & Lomb CorpBLCOEarnings & Financial Report
Bausch & Lomb is an American-Canadian eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. The company was founded in Rochester, New York, in 1853 by optician John Bausch and cabinet maker turned financial backer Henry Lomb. Until its sale in 2013, Bausch + Lomb was one of the oldest continually operating companies in the United States.
BLCO Q4 FY2025 Key Financial Metrics
Revenue
$1.4B
Gross Profit
N/A
Operating Profit
$112.0M
Net Profit
$-58.0M
Gross Margin
N/A
Operating Margin
8.0%
Net Margin
-4.1%
YoY Growth
9.8%
EPS
$-0.16
Bausch & Lomb Corp Q4 FY2025 Financial Summary
Bausch & Lomb Corp reported revenue of $1.4B (up 9.8% YoY) for Q4 FY2025, with a net profit of $-58.0M (down 1833.3% YoY) (-4.1% margin). Cost of goods sold was N/A.
Key Financial Metrics
| Total Revenue | $1.4B |
|---|---|
| Net Profit | $-58.0M |
| Gross Margin | N/A |
| Operating Margin | 8.0% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Bausch & Lomb Corp Q4 FY2025 revenue of $1.4B breaks down across 7 segments, led by Overthe Counter Products at $489.0M (34.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Overthe Counter Products | $489.0M | 34.8% |
| Pharmaceuticals | $378.0M | 26.9% |
| Other | $263.0M | 18.7% |
| Surgical | $249.0M | 17.7% |
| Brandedand Other Generic Products | $14.0M | 1.0% |
| Other Revenues | $3.0M | 0.2% |
| Pharmaceutical Products | $2.0M | 0.1% |
Bausch & Lomb Corp Revenue by Segment — Quarterly Trend
Bausch & Lomb Corp revenue by segment across the last 4 reported quarters, showing how each business line (such as Overthe Counter Products and Pharmaceuticals) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Overthe Counter Products | $489.0M | $454.0M | — | $409.0M |
| Pharmaceuticals | $378.0M | $330.0M | $309.0M | $267.0M |
| Other | $263.0M | $4.0M | $476.0M | $4.0M |
| Surgical | $249.0M | $215.0M | $216.0M | $214.0M |
| Brandedand Other Generic Products | $14.0M | $9.0M | $10.0M | $9.0M |
Bausch & Lomb Corp Annual Revenue by Year
Bausch & Lomb Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $5.1B).
Bausch & Lomb Corp Quarterly Revenue & Net Profit History
Bausch & Lomb Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.4B | +9.8% | $-58.0M | -4.1% |
| Q3 FY2025 | $1.3B | +7.1% | $-28.0M | -2.2% |
| Q2 FY2025 | $1.3B | +5.1% | $-62.0M | -4.9% |
| Q1 FY2025 | $1.1B | +3.5% | $-212.0M | -18.6% |
| Q4 FY2024 | $1.3B | +9.1% | $-3.0M | -0.2% |
| Q3 FY2024 | $1.2B | +18.8% | $4.0M | 0.3% |
| Q2 FY2024 | $1.2B | +17.5% | $-151.0M | -12.4% |
| Q1 FY2024 | $1.1B | +18.0% | $-167.0M | -15.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.10B | $1.22B | $1.20B | $1.28B | $1.14B | $1.28B | $1.28B | $1.41B |
| YoY Growth | 18.0% | 17.5% | 18.8% | 9.1% | 3.5% | 5.1% | 7.1% | 9.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $13.29B | $13.25B | $13.52B | $13.47B | $13.43B | $13.83B | $13.83B | $14.02B |
| Liabilities | $6.56B | $6.67B | $6.85B | $6.92B | $7.00B | $7.32B | $7.33B | $7.50B |
| Equity | $6.66B | $6.50B | $6.59B | $6.47B | $6.36B | $6.44B | $6.43B | $6.45B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $41.0M | $15.0M | $154.0M | $22.0M | $-25.0M | $35.0M | $137.0M | $136.0M |